2431 - 2440 of 8137 Results
Title
Year
-
OPENTitle: NigraNet: An automatic framework to assess nigral neuromelanin content in early Parkinson’s disease using convolutional neural networkJournal Name: NeuroImage: ClinicalPublisher: Elsevier BVVol: 36Issue #:Start Page: 103250End Page: 103250Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.nicl.2022.103250Best OA location URL: https://doi.org/10.1016/j.nicl.2022.103250Citation Count: 8
-
OPENTitle: Pharmacokinetic, pharmacodynamic, and transcriptomic analysis of chronic levetiracetam treatment in 5XFAD mice: A MODEL‐AD preclinical testing core studyJournal Name: Alzheimer's & Dementia: Translational Research & Clinical InterventionsPublisher: WileyVol: 8Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1002/trc2.12329Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398229Citation Count: 13
- Poster Session2022OPENTitle: Poster SessionJournal Name: Rinsho ShinkeigakuPublisher: Societas Neurologica JaponicaVol: 62Issue #: SupplementStart Page: S247End Page: S393Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.5692/clinicalneurol.62_supplement_s247Best OA location URL: https://www.jstage.jst.go.jp/article/clinicalneurol/62/Supplement/62_62_supplement_S247/_pdfCitation Count: 0
-
OPENTitle: POSTERS - 15th Conference Clinical Trials Alzheimer’s Disease, November 29- December 2, 2022, San Francisco, CA, USAJournal Name: The Journal of Prevention of Alzheimer's DiseasePublisher: Elsevier BVVol: 9Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.14283/jpad.2022.97Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734609Citation Count: 4
-
RESTRICTEDTitle: Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier?Journal Name: Clinical Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 7Issue #:Start Page: 100161End Page: 100161Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.prdoa.2022.100161Best OA location URL: https://doi.org/10.1016/j.prdoa.2022.100161Citation Count: 7
-
OPENTitle: Sorting (Nexin-13) out Novel Insights into Endolysosomal Cholesterol ExportJournal Name: ContactPublisher: SAGE PublicationsVol: 5Issue #:Start Page: 251525642211145End Page: 251525642211145Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1177/25152564221114513Best OA location URL: https://journals.sagepub.com/doi/pdf/10.1177/25152564221114513Citation Count: 2
-
OPENTitle: Subcellular and regional localization of mRNA translation in midbrain dopamine neuronsJournal Name: Cell ReportsPublisher: Elsevier BVVol: 38Issue #: 2Start Page: 110208End Page: 110208Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1016/j.celrep.2021.110208Best OA location URL: http://www.cell.com/article/S2211124721017125/pdfCitation Count: 39
-
RESTRICTEDTitle: The many genomes of Parkinson's diseaseJournal Name: International Review of NeurobiologyPublisher: ElsevierVol:Issue #:Start Page: 59End Page: 80Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/bs.irn.2022.07.007Citation Count: 3
-
RESTRICTEDTitle: The neuropsychiatry of Parkinson's disease: advances and challengesJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 1Start Page: 89End Page: 102Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00330-6Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800169Citation Count: 151
-
RESTRICTEDTitle: Therapeutics in the Pipeline Targetingα-Synuclein for Parkinson's DiseaseJournal Name: Pharmacological ReviewsPublisher: American Society for Pharmacology & Experimental Therapeutics (ASPET)Vol: 74Issue #: 1Start Page: 207End Page: 237Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-ncDOI - Digital Object Identifier: 10.1124/pharmrev.120.000133Best OA location URL: https://pharmrev.aspetjournals.org/content/pharmrev/74/1/207.full.pdfCitation Count: 39